Passage Bio, Inc.(PASG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PASG Passage Bio, Inc.

Post-Mkt 12-22 19:29:06 EST

9.99

+0.40

+4.17%

盘后10.07

+0.08+0.80%

17:49 EST

High10.44	Low9.24	Vol20.41K
Open9.53	D1 Closing9.59	Amplitude12.51%
Mkt Cap31.76M	Tradable Cap28.64M	Total Shares3.18M
T/O203.53K	T/O Rate0.71%	Tradable Shares2.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PASG","market":"US","secType":"STK","nameCN":"Passage Bio, Inc.","latestPrice":9.99,"timestamp":1766437200000,"preClose":9.59,"halted":0,"volume":20411,"hourTrading":{"tag":"盘后","latestPrice":10.07,"preClose":9.99,"latestTime":"17:49 EST","volume":755,"amount":7566.97995,"timestamp":1766443793757},"delay":0,"floatShares":2867176,"shares":3178710,"eps":-14.566743,"marketStatus":"Post-Mkt","change":0.4,"latestTime":"12-22 19:29:06 EST","open":9.53,"high":10.44,"low":9.24,"amount":203526.674031,"amplitude":0.12513,"askPrice":10.08,"askSize":300,"bidPrice":4.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.566743,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"listingDate":1582866000000,"exchange":"NASDAQ","adjPreClose":9.59,"postHourTrading":{"tag":"盘后","latestPrice":10.07,"preClose":9.99,"latestTime":"17:49 EST","volume":755,"amount":7566.97995,"timestamp":1766443793757},"volumeRatio":0.333307,"impliedVol":1.9527,"impliedVolPercentile":0.9927},"requestUrl":"/m/hq/s/PASG","defaultTab":"news","newsList":[{"id":"2582376084","title":"Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376084","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376084?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:45","pubTimestamp":1762951544,"startTime":"0","endTime":"0","summary":"Passage Bio (PASG) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PASG"],"gpt_icon":0},{"id":"2582376201","title":"Passage Bio Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376201?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:42","pubTimestamp":1762951320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PASG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 07:42 ET (12:42 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"gpt_icon":0},{"id":"2582347206","title":"Passage Bio (PASG) Receives a Buy from Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582347206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582347206?lang=en_us&edition=fundamental","pubTime":"2025-11-12 15:15","pubTimestamp":1762931717,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits maintained a Buy rating on Passage Bio today and set a price target of $21.00. According to TipRanks, Livsh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/passage-bio-pasg-receives-a-buy-from-chardan-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/passage-bio-pasg-receives-a-buy-from-chardan-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2582109395","title":"Wedbush Adjusts Passage Bio Price Target to $32 From $40, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582109395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582109395?lang=en_us&edition=fundamental","pubTime":"2025-11-12 01:01","pubTimestamp":1762880499,"startTime":"0","endTime":"0","summary":"Price: 6.56, Change: -0.15, Percent Change: -2.16","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2582800079","title":"Passage Bio Unveils Gene Therapy Advances Targeting Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800079","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800079?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:17","pubTimestamp":1762809451,"startTime":"0","endTime":"0","summary":"Passage Bio Inc. presented updates on its gene therapy program PBFT02, which targets frontotemporal dementia with progranulin gene mutations . The therapy is designed as a one-time, proprietary AAV1 gene replacement administered via nonsurgical injection to the cerebrospinal fluid, aiming to restore progranulin levels and address the underlying cause of FTD-GRN. Interim clinical data indicate durable elevation of progranulin in treated patients. The company highlighted the significant market opportunity for PBFT02 across several neurodegenerative diseases, including ALS and Alzheimer's disease associated with GRN mutations. Passage Bio also reported that its current cash position is expected to support operations into the first quarter of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL308F6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2582800743","title":"Passage Bio reports Q3 net loss of $7.7 million on $52.8 million cash balance","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800743?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809319,"startTime":"0","endTime":"0","summary":"Passage Bio Inc. reported a net loss of $7.7 million, or $2.44 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $19.3 million, or $6.15 per share, for the same period in 2024. Research and development expenses were $4.3 million, down from $8.7 million in the prior year quarter. General and administrative expenses were $4.3 million, compared to $7.3 million in the previous year. Cash, cash equivalents, and marketable securities totaled $52.8 million as of September 30, 2025, down from $84.8 million the year before. The company expects its cash resources to fund operations into the first quarter of 2027. Passage Bio is actively enrolling patients in its ongoing upliFT-D study and is on track to seek regulatory feedback on its FTD-GRN registrational trial design in the first half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9TfJCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"gpt_icon":0},{"id":"2582855123","title":"Passage Bio Inc - Cash Runway Extended Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2582855123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582855123?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLXCC9994:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PASG"],"gpt_icon":0},{"id":"2582578385","title":"Passage Bio Inc - Net Loss of $2.44 per Share for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582578385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582578385?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLXCC9994:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2582438556","title":"Passage Bio Inc - on Track to Obtain Regulatory Feedback on Ftd-Grn Registrational Trial Design in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582438556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582438556?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLXCC9994:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2581882136","title":"Passage Bio Inc  expected to post a loss of $2.80 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882136","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882136?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:54","pubTimestamp":1762530845,"startTime":"0","endTime":"0","summary":"Passage Bio Inc  expected to post a loss of $2.80 a share - Earnings Preview Passage Bio Inc PASG.OQ PASG.O is expected to  show no change in quarterly revenue when it reports  results on November 11 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ28B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2581721826","title":"Passage Bio CEO to Join Fireside Chat at Guggenheim Securities Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721826","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721826?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344038,"startTime":"0","endTime":"0","summary":"Passage Bio Inc., a clinical stage genetic medicines company focused on neurodegenerative diseases, will participate in a fireside chat at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on November 12, 2025. A live webcast will be available on the company's website, with a replay accessible for 90 days after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL89fTJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","PASG","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2575291294","title":"Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291294?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Oct.  14, 2025  (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative disease","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166020/0/en/Passage-Bio-to-Participate-in-Chardan-s-9th-Annual-Genetic-Medicines-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","BK4139","PASG"],"gpt_icon":0},{"id":"2567263511","title":"Weston Nichols Reports Acquisition of Common Shares of Passage Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2567263511","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567263511?lang=en_us&edition=fundamental","pubTime":"2025-09-16 08:06","pubTimestamp":1757981185,"startTime":"0","endTime":"0","summary":"Lynx1 Capital Management LP, a beneficial owner, has reported an acquisition of common shares of Passage Bio Inc. The filing was made by more than one reporting person, including Weston Nichols, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nNDL63C8tG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"gpt_icon":0},{"id":"2559966180","title":"Passage Bio Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2559966180","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559966180?lang=en_us&edition=fundamental","pubTime":"2025-08-15 00:39","pubTimestamp":1755189540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PASG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 12:39 ET (16:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG"],"gpt_icon":0},{"id":"2559606036","title":"Passage Bio Inc : Wedbush Adjusts Target Price to $40 From $3 to Reflect 1-for-20 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2559606036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559606036?lang=en_us&edition=fundamental","pubTime":"2025-08-13 18:50","pubTimestamp":1755082242,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2558641396","title":"Passage Bio Inc. Unveils Presentation on Advancements in Gene Therapy for Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2558641396","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558641396?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:23","pubTimestamp":1754997834,"startTime":"0","endTime":"0","summary":"Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia  caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1fFwd4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2558649238","title":"Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649238","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649238?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:08","pubTimestamp":1754996901,"startTime":"0","endTime":"0","summary":"Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of $(5.09) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47054563/passage-bio-q2-eps-2-96-misses-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG"],"gpt_icon":0},{"id":"2558664994","title":"Passage Bio Inc - Cash Runway Extended Into 1Q 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2558664994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558664994?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:00","pubTimestamp":1754996401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA62W9DT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PASG","BK4139"],"gpt_icon":0},{"id":"2558750105","title":"Passage Bio Inc  expected to post a loss of $4.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558750105","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558750105?lang=en_us&edition=fundamental","pubTime":"2025-08-09 00:04","pubTimestamp":1754669098,"startTime":"0","endTime":"0","summary":"Passage Bio Inc  expected to post a loss of $4.05 a share - Earnings Preview Passage Bio Inc PASG.OQ PASG.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U02WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG"],"gpt_icon":0},{"id":"2556823333","title":"Passage Bio Inc  expected to post a loss of $4.05 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556823333","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556823333?lang=en_us&edition=fundamental","pubTime":"2025-08-04 21:25","pubTimestamp":1754313908,"startTime":"0","endTime":"0","summary":"Passage Bio Inc  expected to post a loss of $4.05 a share - Earnings Preview Passage Bio Inc PASG.OQ PASG.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (es","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW16C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.passagebio.com","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":0.217},{"period":"3month","weight":0.3375},{"period":"6month","weight":0.2263},{"period":"1year","weight":-0.2668},{"period":"ytd","weight":-0.1545}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.084009},{"month":2,"riseRate":0.2,"avgChangeRate":0.020018},{"month":3,"riseRate":0,"avgChangeRate":-0.189504},{"month":4,"riseRate":0.5,"avgChangeRate":-0.047034},{"month":5,"riseRate":0.333333,"avgChangeRate":0.016162},{"month":6,"riseRate":0.333333,"avgChangeRate":0.025815},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.14761},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.009674},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.13217},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.009774},{"month":11,"riseRate":0.5,"avgChangeRate":0.171558},{"month":12,"riseRate":0.666667,"avgChangeRate":0.07287}],"exchange":"NASDAQ","name":"Passage Bio, Inc.","nameEN":"Passage Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Passage Bio, Inc.(PASG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Passage Bio, Inc.(PASG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Passage Bio, Inc.,PASG,Passage Bio, Inc.股票,Passage Bio, Inc.股票老虎,Passage Bio, Inc.股票老虎国际,Passage Bio, Inc.行情,Passage Bio, Inc.股票行情,Passage Bio, Inc.股价,Passage Bio, Inc.股市,Passage Bio, Inc.股票价格,Passage Bio, Inc.股票交易,Passage Bio, Inc.股票购买,Passage Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Passage Bio, Inc.(PASG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Passage Bio, Inc.(PASG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction